Coulter Partners strengthens executive and leadership team at Compass Pathways plc
London, September 5, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Compass Pathways (Nasdaq: CMPS) (“Compass”) and is pleased to announce the placement of Gino Santini as Chairman of its Board of Directors and Michael Gold, MD as Chief Research and Development Officer.
Compass is a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health. The Company is pioneering the development of a new model of psilocybin treatment, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
Gino Santini joined the Board of Directors as Chairman, effective 3rd September 2024. David Norton, who has been serving as Interim Chair, continues to be a member of the Board. Mr. Santini brings more than a decade of board leadership and governance expertise in both public and private global corporations, in the US and Europe.
Previously Chief Medical Officer at Neumora Therapeutics, Michael Gold brings more than 25 years of experience across all aspects of drug development in neuroscience, with extensive therapeutic experience in neurological disorders and psychiatric disorders, including depression. Mr. Gold will work with Guy Goodwin, Compass's Chief Medical Officer, to continue developing COMP360 in TRD and other indications, and to explore and advance other potential pipeline opportunities.
Commenting on the collaboration with Coulter Partners, Kabir Nath, Chief Executive Officer of Compass, noted:
Navigating a complex search process, Coulter Partners diligently assessed our business needs and expertly matched our organizational requirements with top talent, leading to two successful appointments. Gino and Mike are important additions for Compass as we expand the breadth and depth of experience across our leadership.
----
Gino Santini, Chairman of Board of Directors
Gino Santini brings more than a decade of board leadership and governance expertise in both public and private global corporations. He currently serves as lead independent director for Collegium Pharmaceuticals (NASDAQ: COLL) and has served as an advisor and board director to US and European venture capital, pharmaceutical, and biotechnology companies since 2011. During his director tenure across more than ten boards, including prior board service at Horizon, Intercept Pharmaceuticals and AMAG Pharmaceuticals, Gino has honed his governance experience as Chairman, Lead Independent Director, and in multiple Committee chair roles. Throughout his nearly three decades at Eli Lilly and Company, he played a leading role in several M&A transactions and led US operations, corporate strategy and business development.
Michael Gold, Chief R&D Officer
A passionate and highly effective pharmaceutical executive, Michael Gold brings more than 25 years of experience across all aspects of drug development in neuroscience to Compass. Before joining Compass, he was Chief Medical Officer at Neumora Therapeutics. Michael has substantial therapeutic experience in neurological disorders and psychiatric disorders, including depression. He has worked extensively with small molecules, biologicals, drug-device combinations, diagnostics and various types of biomarkers. He has significant experience in all segments of the pharmaceutical/ biotechnology sector, including large, small, specialty, start-up and CRO companies. Michael is a highly respected leader in neuroscience drug development and sits on multiple advisory boards. He was selected by the FDA to be the industry representative for advisory committees of the Office of Neuroscience.
